Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
FAQ
- What is Xenon Pharmaceuticals's D&A?
- Xenon Pharmaceuticals (XENE) reported D&A of $558K in Q2 2026.
- How has Xenon Pharmaceuticals's D&A changed year-over-year?
- Xenon Pharmaceuticals's D&A decreased by 11.7% year-over-year, from $632K to $558K.
- What is the long-term trend for Xenon Pharmaceuticals's D&A?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's D&A has grown at a 41.1% compound annual growth rate (CAGR), from $906K to $2.54M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Xenon Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude